Powder: -20°C for 3 years | In solvent: -80°C for 1 year
"ET receptor antagonist 3 (compound 17d) is an orally active ET receptor antagonist with an IC50 of 0.26 nM, utilized for pulmonary arterial hypertension (PAH) research. This compound demonstrates efficacy in mitigating monocrotaline-induced PAH in a rat model [1]."
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
5 mg | Inquiry | Inquiry | |
50 mg | Inquiry | Inquiry |
Description | "ET receptor antagonist 3 (compound 17d) is an orally active ET receptor antagonist with an IC50 of 0.26 nM, utilized for pulmonary arterial hypertension (PAH) research. This compound demonstrates efficacy in mitigating monocrotaline-induced PAH in a rat model [1]." |
In vivo | ET receptor antagonist 3 (compound 17d) administered orally at doses of 150 mg/kg/day and 300 mg/kg/day starting 48 hours after MCT treatment for a total of 21-26 days significantly reduced the mean pulmonary arterial pressure (mPAP) in rats exposed to MCT, and decreased the levels of HIF1α, ANP, and TNNI3. It also exhibited antioxidant activity and inhibited lipid peroxidation [1]. |
Molecular Weight | 548.61 |
Formula | C27H28N6O5S |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
ET receptor antagonist 3 Endocrinology/Hormones Estrogen Receptor/ERR inhibitor inhibit